{"product_id":"1800petmeds-five-forces-analysis","title":"PetMed Express Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003ePetMed Express faces moderate buyer power, intense rivalry from omni-channel pet retailers, and rising substitute threats from vet clinics and DTC brands, while supplier power and entry barriers remain mixed; this snapshot highlights key pressures but doesn’t show the full strategic picture.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Pharmaceutical Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe pet medication market is concentrated: Zoetis, Merck, and Elanco held roughly 60–65% market share in companion-animal pharmaceuticals by sales in 2024, giving suppliers strong leverage.\u003c\/p\u003e\n\u003cp\u003eThese firms control patented drugs—flea, tick, and heartworm treatments—that PetMed Express needs, limiting substitution and price negotiation.\u003c\/p\u003e\n\u003cp\u003ePetMed Express sourced over 70% of its prescription revenue in 2024 from branded meds, constraining margins and sourcing flexibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Distribution Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpmanufacturers increasingly sell direct to vets or via brand e-commerce cutting reliance on third-party retailers like petmed express in an estimated of major pet-pharma sales moved channels per euromonitor. if suppliers restrict online pharmacy access could lose representing roughly sku value hurting gross margins and inventory turnover. this shift raises supplier bargaining power operational risk especially given margin\u003e\n\u003c\/pmanufacturers\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrict Regulatory Compliance Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers must meet strict FDA (Center for Veterinary Medicine) and EPA rules for pet drug manufacture, limiting viable suppliers to a few hundred US-registered facilities; as of 2025 about 12% of veterinary drug makers hold full FDA CVM approval.\u003c\/p\u003e\n\u003cp\u003eThose regulatory barriers mean PetMed Express (NASDAQ: PETS) cannot switch to low-cost or unverified suppliers without risking recalls, fines, or supply interruptions, raising switching costs materially.\u003c\/p\u003e\n\u003cp\u003eAs a result, compliant suppliers keep pricing leverage; in 2024 branded veterinary drug manufacturers reported median gross margins near 62%, supporting strong negotiation positions versus retailers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Proprietary Branding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePet owners and vets often prefer specific brands for chronic treatments like heartworm and flea prevention, forcing PetMed Express to stock those brands and accept supplier terms; in 2024, top brands accounted for roughly 60% of U.S. prescription pet medication sales, reducing retailer leverage.\u003c\/p\u003e\n\u003cp\u003eHigh supplier brand equity limits PetMed Express’s ability to negotiate discounts, pressuring gross margins—PetMed’s 2024 gross margin was ~43%, reflecting constrained pricing flexibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBrand loyalty: ~60% market share concentrated\u003c\/li\u003e\n\u003cli\u003ePetMed gross margin 2024: ~43%\u003c\/li\u003e\n\u003cli\u003eResult: limited discounting power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpsuppliers often set shipping and cold-chain terms for temperature-sensitive pet meds forcing petmed express to accept higher logistics fees fda requirements raise handling costs by an estimated biologics as of\u003e\n\u003cprising freight and api pharmaceutical ingredient prices indices rose in typically passed to retailers petmed express lacking vertical integration cannot produce meds hedge these increases.\u003e\n\u003cpwith gross margin pressure and petmed express sector peers showed contractions of bps in when logistics spiked must raise prices or absorb costs hurting volume margins.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain raises handling costs ~8–12%\u003c\/li\u003e\n\u003cli\u003eAPI prices up ~14% in 2023\u003c\/li\u003e\n\u003cli\u003eSector margins fell 150–250 bps (2022–2024)\u003c\/li\u003e\n\u003cli\u003ePetMed lacks vertical production, limited cost absorption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pwith\u003e\u003c\/prising\u003e\u003c\/psuppliers\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Power Dominates PetMed: Top Brands, High Margins \u0026amp; Cost Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold strong leverage: top firms (Zoetis, Merck, Elanco) ~60–65% share (2024), branded meds = \u0026gt;70% of PetMed prescription revenue (2024), switching costs high due to FDA CVM rules (only ~12% hold full approval by 2025), branded margins ~62% (2024) vs PetMed gross margin ~43% (2024), cold-chain adds ~8–12% cost, API prices +14% (2023).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop suppliers market share (2024)\u003c\/td\u003e\n\u003ctd\u003e60–65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBranded share of PetMed Rx rev (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePetMed gross margin (2024)\u003c\/td\u003e\n\u003ctd\u003e~43%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBranded supplier gross margin (2024)\u003c\/td\u003e\n\u003ctd\u003e~62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain cost uplift (2024)\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI price change (2023)\u003c\/td\u003e\n\u003ctd\u003e+14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA CVM full approval (2025)\u003c\/td\u003e\n\u003ctd\u003e~12% of makers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eUncovers competitive pressures, buyer\/supplier bargaining power, entry barriers, substitutes and rivalry shaping PetMed Express’s pricing, margins and growth prospects, with actionable insights on disruptive threats and strategic defenses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces snapshot for PetMed Express—quickly spot competitive threats, supplier\/buyer leverage, and substitution risks to inform pricing, growth, and defensive strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Pet Owners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCustomers can compare prices across Chewy, Amazon, and local clinics in minutes; 2024 data shows 62% of U.S. pet owners shop online for meds, raising transparency and price pressure.\u003c\/p\u003e\n\u003cp\u003eNo contracts or loyalty locks exist; switching is frictionless, and churn sensitivity rises—PetMed Express reported a 12% revenue decline in price-competitive quarters in 2023 when promotions lagged.\u003c\/p\u003e\n\u003cp\u003eThis ease of movement forces PetMed Express to match discounts and free-shipping offers; average basket price differentials of 8–15% drive price-led retention strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Price Sensitivity in a Fragmented Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising inflation through 2025 has pushed pet-owner price sensitivity: 2024–25 CPI-linked pet care inflation averaged about 6–7%, and 43% of US pet owners report delaying vet care for cost reasons, so small price moves matter. Non-prescription pet supplies are treated as commodities, and many shoppers switch to the lowest-price retailer or promo—PetMedExpress faces competition from Chewy and Amazon on price. This constrains PetMedExpress’s pricing power; a 5% price increase risks measurable share loss given elastic demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Comprehensive Online Information\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe internet gives US pet owners instant access to reviews, price comparison tools, and alternatives; 88% of US pet owners researched pet medications online in 2023, so customers can easily switch retailers. \u003c\/p\u003e\n\u003cp\u003eThis lowers reliance on one seller for advice or selection, forcing PetMed Express (PDEX; NASDAQ: PETS) to fight on price, service, and trust—PDEX reported 2024 gross margin pressure as online competition rose. \u003c\/p\u003e\n\u003cp\u003eTransparency raises demand for superior customer service and value-added features like telehealth, refill reminders, and fast shipping to retain customers. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Veterinary Recommendations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeterinarian recommendations strongly shape purchases: studies show vets influence about 60% of pet prescription decisions, so a vet suggesting in-house dispensing or a favored pharmacy reduces PetMed Express’s capture rate.\u003c\/p\u003e\n\u003cp\u003eThis influencer power means PetMed Express lacks full control even though it sells direct; when vets stock meds, patient retention and order frequency shift toward the vet.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~60% of prescriptions influenced by vets\u003c\/li\u003e\n\u003cli\u003eVets stocking meds cuts third-party sales\u003c\/li\u003e\n\u003cli\u003eRecommendation power weakens direct-control\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of Subscription and Loyalty Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe rise of autoship and subscription models—U.S. pet e‑commerce subscription volume grew ~22% YoY in 2024—locks customers with convenience and 5–20% discounting, raising their bargaining power. If PetMed Express (PetMed Express, Inc., PMED) fails to match rewards or subscription terms, churn risk rises as shoppers shift to Chewy or Amazon Subscribe \u0026amp; Save. Customers now shape retailers’ value propositions via demand for perks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22% U.S. subscription volume growth (2024)\u003c\/li\u003e\n\u003cli\u003eTypical discounts: 5–20% on autoship\u003c\/li\u003e\n\u003cli\u003eChurn risk if PMED lags vs Chewy\/Amazon\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice parity and autoship pressure: vets, online research and 22% YoY autoship growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh price transparency and easy switching give customers strong bargaining power; 62% shop meds online (2024) and 88% researched meds online (2023), forcing price\/promotions parity. Vets influence ~60% of prescriptions, reducing PetMedExpress capture when clinics dispense. Autoship growth (~22% YoY, 2024) and 5–20% subscription discounts increase churn if PMED lags.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline med shoppers (US, 2024)\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearched meds online (2023)\u003c\/td\u003e\n\u003ctd\u003e88%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVets influence\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutoship growth (2024)\u003c\/td\u003e\n\u003ctd\u003e~22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical autoship discount\u003c\/td\u003e\n\u003ctd\u003e5–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003ePetMed Express Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact PetMed Express Porter’s Five Forces analysis you'll receive—fully formatted, professionally written, and ready for immediate download after purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747125703033,"sku":"1800petmeds-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/1800petmeds-five-forces-analysis.png?v=1772195160","url":"https:\/\/matrixbcg.com\/products\/1800petmeds-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}